MRNA
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Moderna, Inc. - Common Stock (MRNA) [ST]
www.modernatx.com ↗▼ 0.55%
prev close
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Congressional Trades
3
All tracked trades
Members Trading
3
Unique members
Net Activity
-3
0 buys · 3 sells
Members Who Traded This Stock
3 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-04-08 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 440d ago | — | |
| 2025-01-15 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 525d ago | — | |
| 2024-02-01 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 867d ago | — |
2025-04-08
Rob Bresnahan
MRNA
Amount
$1,001 - $15,000
Filed
440d ago
2025-01-15
Julie Johnson
MRNA
Amount
$1,001 - $15,000
Filed
525d ago
2024-02-01
Josh Gottheimer
MRNA
Amount
$1,001 - $15,000
Filed
867d ago
Recent News
Powered by Polygon.io
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Moderna Stock Is Soaring. Is It Too Late to Buy?
Trade Timeline
Congressional activity, newest first
Rob Bresnahan
2025-04-08 · Sale
$1,001 - $15,000
Julie Johnson
2025-01-15 · Sale
$1,001 - $15,000
Josh Gottheimer
2024-02-01 · Sale
$1,001 - $15,000